[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:brip1-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"BRIP1 Gene",14,11,[8,16,23,30,36,42,48,54,60,66,72,78,85,92],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05687110","Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes",[12],"Phase 1","RECRUITING","2026-08-26T02:17:58.890423Z","2026-05-05T02:43:27.808389Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT03786796","Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations",[20],"Phase 2","2026-08-26T02:18:38.077159Z","2026-05-05T02:35:31.766251Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT05659381","Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer",[27],"Phase 3","2026-08-26T02:17:14.343713Z","2026-05-05T02:43:27.677486Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT05287451","Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study",[],"2026-08-26T02:15:44.309045Z","2026-07-05T05:32:16.798306Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT04294927","TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention",[],"2026-08-26T02:15:25.633039Z","2026-05-05T02:43:27.631193Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT05941520","Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer",[20],"2026-08-26T02:17:39.048487Z","2026-07-19T19:36:05.126907Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT07645391","Targeted Early Detection Program in Men at High Genetic Risk for Prostate Cancer",[],"2026-08-26T02:16:05.813655Z","2026-06-14T18:39:22.265063Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT05129605","Prostate Cancer Genetic Risk Evaluation and Screening Study",[],"2026-08-26T02:18:25.327036Z","2026-05-13T02:55:06.292506Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT04706663","Precision-Based Genomics in Prostate Cancer",[],"2026-08-26T02:17:23.750999Z","2026-05-13T02:55:06.268346Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT03805919","Men at High Genetic Risk for Prostate Cancer",[],"2026-08-26T02:15:18.897219Z","2026-05-13T02:55:06.177945Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT04038502","Carboplatin or Olaparib for BRcA Deficient Prostate Cancer",[20],"2026-08-26T02:18:40.612983Z","2026-05-05T02:43:29.505079Z",{"nct_id":79,"title":80,"phases":81,"status":82,"updated_at":83,"content_modified":84},"NCT07723651","[18F]Fluorthanatrace - Positron Emission Tomography (FTT-PET) and ctDNA to Predict Response to PARP Inhibitor Therapy in Metastatic Prostate Cancer (mPC)",[20],"NOT_YET_RECRUITING","2026-08-26T02:19:11.399072Z","2026-07-24T01:27:14.924205Z",{"nct_id":86,"title":87,"phases":88,"status":89,"updated_at":90,"content_modified":91},"NCT06212583","High-Risk Metachronous Oligometastatic Prostate Cancer Trial",[20],"ACTIVE_NOT_RECRUITING","2026-08-03T02:25:31.771325Z","2026-05-05T02:43:29.167176Z",{"nct_id":93,"title":94,"phases":95,"status":89,"updated_at":96,"content_modified":97},"NCT05498272","Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations",[20],"2026-08-03T02:05:27.322885Z","2026-05-05T02:43:27.674415Z"]